[Skip to Navigation]
Sign In
Comment & Response
May 2018

Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia—Reply

Author Affiliations
  • 1Division of Hematology, Mayo Clinic, Rochester, Minnesota
JAMA Oncol. 2018;4(5):745-746. doi:10.1001/jamaoncol.2017.5100

In Reply The mSMART consensus statements take into account evidence-based approaches reflecting our preferred and tested management strategies in Waldenström macroglobulinemia (WM), outside clinical trials, and are published to facilitate delivery of high-quality care, particularly by clinicians who infrequently encounter this rare cancer. We recognize the paucity of high-level evidence in WM and have already highlighted in Table 3 of our article the key differences with the other existing guidelines that Castillo and colleagues from the Dana-Farber Cancer Institute point out.1

Add or change institution